Ibuprofen Versus Ketorolac For Postoperative Pain Relief After Cesarean Section

Sponsor
Alexandria University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05907993
Collaborator
(none)
50
1
2
7.9
6.3

Study Details

Study Description

Brief Summary

The aim of this study will be to evaluate the effectiveness of intravenous ibuprofen versus intravenous ketorolac for postoperative pain relief after caesarian section

  1. The Primary outcome is measurement of visual analogue score during rest and movement

  2. The Secondary outcome is measurement of 24 hours opioids requirements.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ibuprofen 800 mg
Phase 4

Detailed Description

METHODS

  1. Preoperative assessment:
All parturients included in the study will be assessed thoroughly by:
  1. Proper history taking

  2. Complete clinical examination.

  3. All needed laboratory investigations.

  4. Patient preparation:

  • On arrival to the operative theatre , an 18 G intravenous cannula will be inserted in a peripheral vein

  • Steps of general anaesthesia will be explained to the parturients.

Using a multichannel monitor (mindary) iMeC12 SHENZEN MINDRAY BIO-MEDICAL ELECTRONICS CO,

LTD, CHINA, the parturients will be continuously monitored for:
  1. Non-invasive arterial blood pressure (NIBP) in (mmHg).

  2. Heart rate (beats/min).

  3. Oxygen saturation (percentage).

  4. End tidal carbon dioxide(mmhg). 3. Anaesthesia technique:

  • Left uterine displacement will be maintained by a wedge under the right hip.

  • Preoxygenation with 100% oxygen will be done for 3-5 minutes

  • For both groups rapid sequence induction will be done with 2mg/kg propofol and 0.9 mg/kg rocuronium,50 microgram fentanyl followed by tracheal intubation and IPPV volume control.

  • Anaesthesia will be maintained with 1.2% isoflurane in 100% Oxygen and 0.1 mg /kg roccuronium will be administrated if needed.

  • After delivery oxytocin infusion 10 IU will be given

  • After finishing operation , inhalational anaesthesia will be stopped and all parturients will receive 2mg/kg sugammadex when train of four is 75%.

  • Then all parturients will be discharged to ward to be put under observation for 24 hours and they will receive NSAID immediately on arrival to the ward .

  • Group A parturients will receive 30 mg ketorolac in 200 cc normal saline intravenously every 6 hours

  • Group B parturients will receive 800 mg Ibuprofen in 200 cc normal saline intravenously every 6 hours

  • All Parturients will receive 25 mg pethidine if visual analogue score (VAS) ≥4.

MEASUREMENTS

The following parameters will be measured for all parturients, in both groups:
  1. Demographic data:

Age (years) Body Mass index ( kilogram/meters2) Weight (kilograms) Height (meters) Duration of surgery (minutes)

  1. Postoperative hemodynamics:
  • Heart rate (beats/min)

  • Blood pressure (mmHg)

  1. Baseline value immediately after extubation before giving any analgesia.

  2. Immediately and 2, 4, 6, 12, 24 hours after end of surgery.

  3. Visual analogue score:

  • All parturients will be trained to use VAS. VAS at rest (VASR) and during movement (VASM) will be measured at 1,3,6,12,18,24 hours following surgery .The VAS score will be presented as 10 cm horizontal line anchored by the words "no pain"(corresponding to zero) and "worst pain possible"(corresponding to ten).The values will be scored as mild pain(from 1 to 3) ,moderate pain (from 4 to 6) and severe pain (from 7 to 10).

  • If VAS is ≥4 parturients will receive 25mg pethidine iv.

  1. Opioid requirement During the first 24 hours after surgery(mg) The doses of pethidine required during the first 24 hours postoperatively will be calculated.

  2. Nocturnal awakening due to pain (percentage) The percentage of parturients who become awake at night due to pain

  3. Time to ambulate (minutes) The time the parturient takes to get out of bed and to do light activities such as sitting, standing or walking.

  4. Time to first analgesic dose (minutes) rescue analgesia The time when the patient require the first analgesic dose in the ward.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effectiveness Of Intravenous Ibuprofen Versus Intravenous Ketorolac For Postoperative Pain Relief After Cesarean Section
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Group (A):

30mg ketorolac in 200cc normal saline intravenously every 6hours for 24hours postoperatively.

Active Comparator: Group (B):

800mg ibuprofen in 200cc normal saline intravenously every 6 hours for 24hours postoperatively.

Drug: Ibuprofen 800 mg
Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief

Outcome Measures

Primary Outcome Measures

  1. measurement of visual analogue score [after the surgery average 24 hours postoperative]

    measurement of visual analogue score during rest and movement . The Score range from 0- 10 . 0 means no pain and 10 indicates the worst pain ever

Secondary Outcome Measures

  1. opioids requirements. [after the surgery average 24 hours postoperative]

    Total opioid cumulative requirement dose

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Parturients aged 20-30years.

  2. ASA physical satatus: II.

  3. Anticipated hospital stay for at least 24 hours.

  4. Refusal of spinal anaesthesia.

Exclusion Criteria:
  1. Known allergy to the used drugs.

  2. Renal and hepatic impairement

  3. History of brochial asthma.

  4. Low platelets count (<70000).

  5. Bleeding diathesis and with history or risk of intracranial hemorrhage.

  6. Obese and morbidly obese parturients.

  7. GIT problems as gastritis or GI bleeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ahmed S. Shehab Alexandria Egypt 21431

Sponsors and Collaborators

  • Alexandria University

Investigators

  • Principal Investigator: Ahmed S. Shehab, MD, Alexandria University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Ahmed Shehab, MD, lecturer Of Anaesthesia and Surgical intensive care, Alexandria University
ClinicalTrials.gov Identifier:
NCT05907993
Other Study ID Numbers:
  • 0107307
First Posted:
Jun 18, 2023
Last Update Posted:
Jun 26, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ahmed Shehab, MD, lecturer Of Anaesthesia and Surgical intensive care, Alexandria University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2023